Patents Assigned to ONCOCEUTICS, INC.
  • Patent number: 11976068
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: May 7, 2024
    Assignee: ONCOCEUTICS, INC.
    Inventors: Joshua E. Allen, Martin Stogniew, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson, Yanjun Sun
  • Patent number: 10953014
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 23, 2021
    Assignee: ONCOCEUTICS, INC.
    Inventors: Martin Stogniew, Joshua E. Allen
  • Patent number: 10946022
    Abstract: Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: March 16, 2021
    Assignee: ONCOCEUTICS, INC.
    Inventors: Joshua E. Allen, Martin Stogniew, Varun Vijay Prabhu
  • Publication number: 20190194201
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Application
    Filed: February 27, 2019
    Publication date: June 27, 2019
    Applicant: ONCOCEUTICS, INC.
    Inventors: Joshua E. ALLEN, Martin STOGNIEW, Richard S. POTTORF, Bhaskara Rao NALLAGANCHU, Gary OLSON, Yanjun SUN
  • Publication number: 20180072729
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 15, 2018
    Applicant: ONCOCEUTICS, INC.
    Inventors: Joshua E. ALLEN, Martin STOGNIEW, Richard S. POTTORF, Bhaskara Rao NALLAGANCHU, Gary OLSON, Yanjun SUN
  • Publication number: 20170096431
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Application
    Filed: February 22, 2016
    Publication date: April 6, 2017
    Applicants: ONCOCEUTICS INC., PROVID PHARMACEUTICALS INC.
    Inventors: Joshua E. Allen, Martin Stogniew, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson, Yanjun Sun
  • Publication number: 20160264574
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): (structurally represented) or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Application
    Filed: September 12, 2014
    Publication date: September 15, 2016
    Applicants: ONCOCEUTICS, INC., PROV PHARMACEUTICALS INC.
    Inventors: Martin STOGNIEW, Joshua E ALLEN, Richard S. POTTORF, Bhaskara Rao NALLAGANCHU, Gary OLSON
  • Publication number: 20140335048
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Applicant: ONCOCEUTICS, INC.
    Inventors: Martin STOGNIEW, Joshua E. ALLEN
  • Publication number: 20140271540
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: ONCOCEUTICS, INC.
    Inventors: Martin STOGNIEW, Joshua E. ALLEN